Introduction Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus and the leading cause of impaired vision in adults worldwide. Early detection and treatment for DR ...

Treatment of hypertensive retinopathy begins with controlling hypertension. Some of the complications can be treated by an ophthalmologist with injectable medications into the eye as well as laser ...

Retinopathy is considered one of the indicators of target organ damage. This review focuses on recent studies on hypertensive retinopathy and their implications for clinical care. Early recognition of ...

Kaiser shared data from the phase 1 HELIOS trial that showed stability or improvement in diabetic retinopathy at 1 year after treatment with the implant. Patients also saw improvements in diabetic ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

1 School of Intelligence Engineering, Shandong Management University, Jinan, China 2 Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ...

Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR) in type 2 diabetic patients and their contributing factors. Methods: 199 type 2 ...

Abstract: Diabetic retinopathy (DR) is a severe complication of diabetes that affects the retinal structures and can lead to significant visual impairment or even blindness. Early diagnosis is crucial ...

The growing global prevalence of diabetes mellitus (DM), along with its associated complications, continues to rise. When clinically detected most DM complications are irreversible. It is therefore ...

Lastly, registration of retinopathy was restricted to participant recollection and reporting. Objective measures or consultation in patient records would have improved the validity of this outcome. We ...

From Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Victoria, Australia (R.H.R.) Division of Endocrinology and Metabolism (E.D.A.), ...